New drug NEOK001 targets Hard-to-Treat cancers in first human trial
NCT ID NCT07612176
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called NEOK001 in people with advanced solid tumors that have stopped responding to standard treatments. NEOK001 is designed to deliver a cancer-killing agent directly to tumor cells by targeting two specific proteins. The study will first find the safest dose and then expand to see how well the drug works in about 155 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NEOK001 (a bispecific antibody-drug conjugate targeting B7-H3 and ROR1)
- What this could lead to
- If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
- What could go wrong
- This is a very early Phase 1 trial, so the drug may not be effective or could cause significant side effects. It is also a small study, so results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
NOT_YET_RECRUITINGNew York, New York, 10065, United States
-
NEXT Oncology
NOT_YET_RECRUITINGAustin, Texas, 78758, United States
-
NEXT Oncology
NOT_YET_RECRUITINGDallas, Texas, 75039, United States
-
NEXT Oncology
NOT_YET_RECRUITINGHouston, Texas, 77054, United States
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78299, United States
-
NEXT Oncology
NOT_YET_RECRUITINGFairfax, Virginia, 22031, United States
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug targets Hard-to-Treat cancers by homing in on a specific protein
- New drug combo aims to tackle Hard-to-Treat HER2 cancers
- New drug aims to shrink hard-to-treat tumors
- New drug IBI133 tested in 19 patients with Hard-to-Treat cancers
- New drug IBI343 takes on advanced cancers in first human trial